Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 33 Issue 5
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2015  >  33(5): 385-388,422

HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
Citation: HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
shu

Gut microbiota and inflammatory bowel disease

doi: 10.3969/j.issn.1006-0111.2015.05.001
  • 1.

    New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 2.

    Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China

  • 3.

    School of Medicine, Tongji University, Shanghai 200092, China

  • Received Date: 2014-11-13
  • Rev Recd Date: 2015-03-17
  • Inflammatory bowel disease is a chronic inflammation of the intestinal tract, which comprises two primary forms of Crohn's disease(CD) and ulcerative colitis(UC). Decades of studies have revealed that environmental factors, susceptibility genes, and gut microbiota are considered as the major determinants for the induction of IBD. The combination of factors has made IBD as an appropriate and a high-priority platform for studying host-microbiome interactions. More recently, profiling studies of the intestinal microbe have associated pathogenesis of IBD with characteristic alterations in the composition of the intestinal microbiota,reinforcing the viewpoint that IBD results from the altered interplays between the host and intestinal microbe. the studies of the gut flora in IBD were reviewed andthe multiple effects of intestinal microbiota-dysfunction on the IBD were described.The progress of intestinal microbiota alterations with different therapeutic methods in animal models and clinic trials were provided.
  • [1] Molodecky NA,Soon IS,Rabi DM,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012, 142(1):46-54.
    [2] Dave M,Higgins PD,Middha S,et al. The human gut microbiome: current knowledge,challenges,and future directions[J].Transl Res,2012,160(4):246-257.
    [3] Huttenhower C,Kostic AD,Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome[J]. Immunity,2014,40(6):843-854.
    [4] Morgan XC,Segata N,Huttenhower C. Biodiversity and functional genomics in the human microbiome[J]. Trends Genet,2013,29(1):51-58.
    [5] Scaldaferri F,Gerardi V,Lopetuso LR,et al. Gut microbial flora,prebiotics,and probiotics in IBD: their current usage and utility[J]. Biomed Res Int,2013,2013:435268.
    [6] Hooper LV,Littman DR,Macpherson AJ. Interactions between the microbiota and the immune system[J].Science,2012,336(6086):1268-1273.
    [7] Boudeau J,Glasser AL,Masseret E,et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease[J].Infect Immun,1999,67(9):4499-4509.
    [8] Rolhion N,Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Inflamm Bowel Dis,2007,13(10):1277-1283.
    [9] Allen-Vercoe E,Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC?[J].Immunol Lett,2014,162(2PA):54-61.
    [10] Allen-Vercoe E,Strauss J,Chadee K. Fusobacterium nucleatum: an emerging gut pathogen?[J].Gut Microb,2011,2(5):294-298.
    [11] Ohkusa T,Okayasu I,Ogihara T,et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J]. Gut,2003,52(1):79-83.
    [12] Strauss J,Kaplan GG,Beck PL,et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host[J]. Inflamm Bowel Dis,2011,17(9):1971-1978.
    [13] Kostic AD,Chun E,Robertson L,et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microb,2013,14(2):207-215.
    [14] Kitajima S,Morimoto M,Sagara E,et al. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice[J]. Exp Anim,2001,50(5):387-395.
    [15] Kamada N,Chen G,Núez G. A complex microworld in the gut: harnessing pathogen-commensal relations[J]. Nat Med,2012,18(8):1190-1191.
    [16] Llopis M,Antolin M,Carol M,et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa[J]. Inflamm Bowel Dis,2009,15(2):275-283.
    [17] Varela E,Manichanh C,Gallart M,et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis[J]. Aliment Pharmacol Ther,2013,38(2):151-161.
    [18] Cadwell K,Patel KK,Maloney NS,et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine[J]. Cell,2010,141(7):1135-1145.
    [19] Trojanowska D,Zwolinska-Wcislo M,Tokarczyk M,et al. The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains[J]. Med Sci Monit,2010,16(10):CR451-457.
    [20] Iliev ID,Funari VA,Taylor KD,et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis[J]. Science,2012,336(6086):1314-1317.
    [21] Morgan XC,Tickle TL,Sokol H,et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J]. Genome Biol,2012,13(9):R79.
    [22] Atarashi K,Tanoue T,Oshima K,et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota[J]. Nature,2013,500(7461):232-236.
    [23] Duncan SH,Hold GL,Barcenilla A,et al.Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces[J]. Int J Syst Evol Microbiol, 2002,52(Pt 5):1615-1620.
    [24] Khan KJ,Ullman TA,Ford A,et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and Meta-analysis[J]. Am J Gastroenterol,2011,106(4):661-673.
    [25] Lemon KP,Armitage GC,Relman DA,et al. Microbiota-targeted therapies: an ecological perspective[J]. Sci Transl Med,2012,4(137):137rv5.
    [26] Gevers D,Kugathasan S,Denson LA,et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microb,2014,15(3):382-392.
    [27] Wlodarska M,Willing B,Keeney KM,et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium induced colitis[J]. Infect Immun,2011,79(4):1536-1545.
    [28] Damman CJ,Miller SI,Surawicz CM,et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?[J].Am J Gastroenterol,2012,107(10):1452-1459.
    [29] Shahinas D,Silverman M,Sittler T,et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing[J]. MBio,2012,3(5):e00338-12.
    [30] Anderson JL,Edney RJ,Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Aliment Pharmacol Ther,2012,36(6):503-516.
    [31] Morgan XC,Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome[J]. Gastroenterology,2014,146(6):1437-1448.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0400.250.50.7511.25Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 80.9 %FULLTEXT: 80.9 %META: 17.6 %META: 17.6 %PDF: 1.5 %PDF: 1.5 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 33.0 %其他: 33.0 %其他: 1.7 %其他: 1.7 %Albania: 0.4 %Albania: 0.4 %Canada: 0.4 %Canada: 0.4 %China: 0.7 %China: 0.7 %France: 0.4 %France: 0.4 %Grove City: 0.4 %Grove City: 0.4 %Israel: 0.4 %Israel: 0.4 %Japan: 0.4 %Japan: 0.4 %Norway: 0.9 %Norway: 0.9 %Taoyuan District: 0.2 %Taoyuan District: 0.2 %United States: 0.4 %United States: 0.4 %[]: 1.1 %[]: 1.1 %上海: 3.3 %上海: 3.3 %北京: 8.5 %北京: 8.5 %南京: 0.4 %南京: 0.4 %厦门: 0.7 %厦门: 0.7 %圣路易斯: 0.9 %圣路易斯: 0.9 %大连: 0.2 %大连: 0.2 %天津: 0.4 %天津: 0.4 %安顺: 0.2 %安顺: 0.2 %密蘇里城: 0.4 %密蘇里城: 0.4 %悉尼: 0.4 %悉尼: 0.4 %成都: 0.4 %成都: 0.4 %杭州: 0.4 %杭州: 0.4 %森尼韦尔: 0.4 %森尼韦尔: 0.4 %武汉: 0.2 %武汉: 0.2 %沈阳: 0.2 %沈阳: 0.2 %科隆: 0.4 %科隆: 0.4 %罗奥尔凯埃: 0.4 %罗奥尔凯埃: 0.4 %芒廷维尤: 15.0 %芒廷维尤: 15.0 %衢州: 0.2 %衢州: 0.2 %西宁: 23.0 %西宁: 23.0 %达曼: 0.4 %达曼: 0.4 %运城: 0.2 %运城: 0.2 %郑州: 0.2 %郑州: 0.2 %都柏林: 0.4 %都柏林: 0.4 %重庆: 0.2 %重庆: 0.2 %长沙: 0.7 %长沙: 0.7 %长治: 0.2 %长治: 0.2 %青岛: 0.2 %青岛: 0.2 %黄冈: 0.7 %黄冈: 0.7 %其他其他AlbaniaCanadaChinaFranceGrove CityIsraelJapanNorwayTaoyuan DistrictUnited States[]上海北京南京厦门圣路易斯大连天津安顺密蘇里城悉尼成都杭州森尼韦尔武汉沈阳科隆罗奥尔凯埃芒廷维尤衢州西宁达曼运城郑州都柏林重庆长沙长治青岛黄冈Highcharts.com

  • Cited by

    Periodical cited type(3)

    1. 李兆龙，刘金林，陈新福，李东娅，罗锦义，黄耿光. 复合微生物在畜禽养殖中的应用与发展前景. 福建畜牧兽医. 2020(05): 21-24 .
    2. 袁磊，蒋逍达，季梦遥. 缓解期炎症性肠病病人的护理进展. 护理研究. 2018(18): 2826-2830 .
    3. 仲婕，陈健海，翟达，卜平. 炎症性肠病病理生理学机制研究进展. 胃肠病学和肝病学杂志. 2016(07): 733-735 .

    Other cited types(4)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(4105) PDF downloads(592) Cited by(7)

Related
Proportional views

Gut microbiota and inflammatory bowel disease

doi: 10.3969/j.issn.1006-0111.2015.05.001
  • 1. New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
  • 2. Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China
  • 3. School of Medicine, Tongji University, Shanghai 200092, China
  • Received Date: 2014-11-13
  • Rev Recd Date: 2015-03-17

Abstract: Inflammatory bowel disease is a chronic inflammation of the intestinal tract, which comprises two primary forms of Crohn's disease(CD) and ulcerative colitis(UC). Decades of studies have revealed that environmental factors, susceptibility genes, and gut microbiota are considered as the major determinants for the induction of IBD. The combination of factors has made IBD as an appropriate and a high-priority platform for studying host-microbiome interactions. More recently, profiling studies of the intestinal microbe have associated pathogenesis of IBD with characteristic alterations in the composition of the intestinal microbiota,reinforcing the viewpoint that IBD results from the altered interplays between the host and intestinal microbe. the studies of the gut flora in IBD were reviewed andthe multiple effects of intestinal microbiota-dysfunction on the IBD were described.The progress of intestinal microbiota alterations with different therapeutic methods in animal models and clinic trials were provided.

HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
Citation: HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
shu

    HTML

Reference (31)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return